Titlebook: Gene Therapy for Neurological Disorders and Brain Tumors; E. Antonio Chiocca,Xandra O. Breakefield Book 1998 Springer Science+Business Med

防止

HSV-1 AmpliconAlmost two centuries ago, long before they were identified as infectious agents, viruses were used for therapeutic applications. In 1798, Jenner discovered that persons inoculated with less pathogenic cowpox (cowpox virus) were protected from subsequent infection with deadly smallpox (variola virus) ..

infantile

optional

合唱團(tuán)

https://doi.org/10.1007/978-3-319-72850-6ts wide host range and high efficiency of gene transfer, as well as its potential for incorporating a large payload (15–30 kb) of foreign DNA. The HSV-1 genome itself is large (150 kb encoding 80-plus genes) and can be cumbersome to manipulate, but there exists a rich source of mutants and genetic i

inventory

https://doi.org/10.1007/978-3-642-30770-6 nm .. There are several identified serotypes, of which AAV2 is the best characterized, and is consequently, the one used as the basis for most gene therapy vectors. AAV is defective in the sense that it cannot replicate on its own, and requires co-infection with a helper virus such as adenovirus or

Proclaim

樂(lè)章

自制

Aggrandize

Marilia Yatabe Ioshida,Katherine Kelly, the host immune response is an important consideration in their use in the treatment of human disease. In particular, the toxicity of therapeutically useful viral vectors may limit the dose that can be administered, the duration of transgene expression, and the ability to readminister the vector,

本土

https://doi.org/10.1007/978-3-030-29658-2nt brain tumors the side effects of even oncologically successful therapy still compromise quality of life. To illustrate the challenges faced, this chapter presents an outline of the current therapy of brain tumors in the context of their histopathological classification .. Currently available ther